IL128850A - Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture - Google Patents

Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Info

Publication number
IL128850A
IL128850A IL12885097A IL12885097A IL128850A IL 128850 A IL128850 A IL 128850A IL 12885097 A IL12885097 A IL 12885097A IL 12885097 A IL12885097 A IL 12885097A IL 128850 A IL128850 A IL 128850A
Authority
IL
Israel
Prior art keywords
cyclobutyl
chlorophenyl
unsubstituted
humans
substituted
Prior art date
Application number
IL12885097A
Other languages
English (en)
Other versions
IL128850A0 (en
Original Assignee
Abott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abott Gmbh & Co Kg filed Critical Abott Gmbh & Co Kg
Publication of IL128850A0 publication Critical patent/IL128850A0/xx
Publication of IL128850A publication Critical patent/IL128850A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
IL12885097A 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture IL128850A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (2)

Publication Number Publication Date
IL128850A0 IL128850A0 (en) 2000-01-31
IL128850A true IL128850A (en) 2003-07-31

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12885097A IL128850A (en) 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Country Status (26)

Country Link
US (3) US6174925B1 (xx)
EP (1) EP0927028A1 (xx)
JP (1) JP2001503737A (xx)
KR (1) KR20000048501A (xx)
CN (1) CN1237905A (xx)
AU (1) AU724488B2 (xx)
BG (1) BG64473B1 (xx)
BR (1) BR9711517A (xx)
CA (1) CA2266401C (xx)
CZ (1) CZ93699A3 (xx)
GB (1) GB9619757D0 (xx)
HR (1) HRP970505A2 (xx)
HU (1) HUP9904026A3 (xx)
ID (1) ID18320A (xx)
IL (1) IL128850A (xx)
MY (1) MY116150A (xx)
NO (1) NO991358L (xx)
NZ (1) NZ334580A (xx)
PL (1) PL332305A1 (xx)
RU (1) RU2245709C2 (xx)
SK (1) SK31999A3 (xx)
TR (1) TR199900618T2 (xx)
TW (1) TW580385B (xx)
UA (1) UA64726C2 (xx)
WO (1) WO1998011884A1 (xx)
ZA (1) ZA978450B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
AU754740B2 (en) * 1998-06-30 2002-11-21 Takeda Chemical Industries Ltd. Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
DE69939485D1 (de) * 1998-11-12 2008-10-16 Smithkline Beecham Plc Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
MXPA01012494A (es) 1999-06-01 2002-07-02 Univ Texas Southwestern Med Ct Metodo para tratar perdida capilar con el uso de compuestos sulfonil tiromimeticos.
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
CA2501321C (en) * 2002-10-05 2008-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
AR045330A1 (es) * 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
AU2004285354B2 (en) 2003-10-31 2009-09-17 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
JP5432526B2 (ja) 2006-01-06 2014-03-05 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害剤としてのシクロアルキルアミン
EP2066329B1 (en) 2006-09-15 2017-09-06 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cyclobutylmethylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
JP2010510306A (ja) * 2006-11-22 2010-04-02 エスケー ケミカルズ カンパニー リミテッド シブトラミンとベータ−シクロデキストリンの包接複合体
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
JP6450191B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
EP0927028A1 (en) 1999-07-07
AU724488B2 (en) 2000-09-21
JP2001503737A (ja) 2001-03-21
SK31999A3 (en) 1999-12-10
TR199900618T2 (xx) 1999-06-21
NZ334580A (en) 2000-09-29
KR20000048501A (ko) 2000-07-25
UA64726C2 (uk) 2004-03-15
TW580385B (en) 2004-03-21
MY116150A (en) 2003-11-28
BG64473B1 (bg) 2005-04-30
HUP9904026A2 (hu) 2000-05-28
GB9619757D0 (en) 1996-11-06
BG103277A (en) 2000-01-31
NO991358D0 (no) 1999-03-19
CN1237905A (zh) 1999-12-08
IL128850A0 (en) 2000-01-31
CA2266401C (en) 2007-01-30
HUP9904026A3 (en) 2000-07-28
NO991358L (no) 1999-03-19
US6174925B1 (en) 2001-01-16
HRP970505A2 (en) 1998-08-31
RU2245709C2 (ru) 2005-02-10
US6617360B1 (en) 2003-09-09
CZ93699A3 (cs) 1999-08-11
WO1998011884A1 (en) 1998-03-26
US20040077730A1 (en) 2004-04-22
CA2266401A1 (en) 1998-03-26
BR9711517A (pt) 1999-08-24
AU4774097A (en) 1998-04-14
PL332305A1 (en) 1999-08-30
ZA978450B (en) 1999-03-19
ID18320A (id) 1998-03-26

Similar Documents

Publication Publication Date Title
IL128850A (en) Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture
IL110978A0 (en) 17beta -anilide-4-aza- 5alpha -androst-1-en-3-one derivative, its preparation and pharmaceutical co mposition containing it
US5993653C1 (en) Composition and column used in hplc
HUP0004300A3 (en) Pharmaceutical composition comprising (s)-n-ethyl-3-[1-(dimethylamino)ethyl]-n-methyl-phenyl-carbamate and an antioxidant
AP9801407A0 (en) Substituted 3,5-diphen l-1,2 4-triazoles and their use as pharmaceutical metal chelators
HUP0200709A3 (en) Triazole compounds with dopamine-d3-receptor affinity, pharmaceutical compositions containing them and their use
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
HUP0100064A3 (en) Synergetic fungicidal combination comprising amides derivative and chlorothalonil and its use
HUP0202648A3 (en) Imidazolyl derivatives, pharmaceutical compositions containing them and their use
HU9600813D0 (en) Azole derivatives and pharmaceutical composition thereof
HUP0000145A3 (en) Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them
GB9520584D0 (en) Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
ZA947710B (en) Imidazol-4 ylpiperdine derivatives, their preparation and their application in therapeutics.
IL123013A (en) Substituted imidazoles having biphenylsulfonyl substitution, and pharmaceutical compositions comprising them
HUP0100717A3 (en) Synergetic fungicidal composition comprising amide compound and its use
HU9600427D0 (en) Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
IL118644A0 (en) N-Ú(1,4-diazabicyclo Ú2.2.2¾ oct-2-yl) methyl¾ benzamide derivatives their preparation and their application in therapeutics
IL118142A (en) Pharmaceutical composition containing tiagabine hydrochloride together with antioxidants and its preparation
HK1048917A1 (zh) 含有n-丙酮基苯甲酰胺和滅菌丹的殺真菌組合物
GB9310075D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL109438A0 (en) 3-Quinolyl-substituted dihydropyridines, processes for their preparation and their use in pharmaceutical compositions
HUP0003074A3 (en) Pharmaceutical composition comprising ssri and betha-blocking agent
HUP0002975A3 (en) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate and pharmaceutical composition containing it
HUP0104623A3 (en) Cyclosporin solution, pharmaceutical composition comprising thereof and its use
HUP9903098A3 (en) Combination comprising vx478, zidovudine and/or 1592u89 and pharmaceutical composition containing them

Legal Events

Date Code Title Description
HCA Change of name of proprietor(s) after amalgamation
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees